Belgium (BE)

The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity (2018) Colombo M, Lopez-Perolio I, Meeks HD, Caleca L, Parsons MT, Li H, De Vecchi G, et al. Journal article Combined PET/MRI: Global Warming—Summary Report of the 6th International Workshop on PET/MRI, March 27–29, 2017, Tübingen, Germany (2018) Bailey DL, Pichler BJ, Gueckel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, et al. Journal article, Original article Robust feedback control of continuously operated convective dryers for particulate materials (2018) Seidel C, Neugebauer C, Durr R, Bück A Conference contribution A mixed finite element method for elliptic operators with Wentzell boundary condition (2018) Bänsch E, Gahn M Journal article, Original article Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma (2018) Megremis S, Niespodziana K, Cabauatan C, Xepapadaki P, Kowalski ML, Jartti T, Bachert C, et al. Journal article Contribution of repeated infections in asthma persistence from preschool to school age: Design and characteristics of the PreDicta cohort (2018) Xepapadaki P, Bachert C, Finotto S, Jartti T, Konstantinou GN, Kiefer A, Kowalski M, et al. Journal article ESTRO-ACROP guideline: Interstitial multi-catheter breast brachytherapy as Accelerated Partial Breast Irradiation alone or as boost - GEC-ESTRO Breast Cancer Working Group practical recommendations (2018) Strnad V, Major T, Polgar C, Lotter M, Guinot JL, Gutierrez-Miguelez C, Galalae R, et al. Journal article Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity-Score Matched Cohort Analysis (2018) Levi JMH, Van Limbergen E, Gal J, Schiappa R, Polgar C, Kauer-Dorner D, Pasquier D, et al. Conference contribution Pitfalls in the measurement of muscle mass: a need for a reference standard (2018) Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, Maggi S, et al. Journal article Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial (2018) Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, et al. Journal article